Cargando…

209. What’s So Complicated About Complicated Staphylococcus aureus Bacteremia: Does Day 5 Matter?

BACKGROUND: Prolonged Staphylococcus aureus bacteremia (SAB) poses challenges in clinical practice, particularly when a source is not readily identified. While SAB greater than 3 days has been identified as a risk factor for complications, little is known about risk for specific complications with e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilsendager, Cami, Strnad, Luke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810339/
http://dx.doi.org/10.1093/ofid/ofz360.284
_version_ 1783462227064389632
author Hilsendager, Cami
Strnad, Luke
author_facet Hilsendager, Cami
Strnad, Luke
author_sort Hilsendager, Cami
collection PubMed
description BACKGROUND: Prolonged Staphylococcus aureus bacteremia (SAB) poses challenges in clinical practice, particularly when a source is not readily identified. While SAB greater than 3 days has been identified as a risk factor for complications, little is known about risk for specific complications with each successive day of bacteremia. We sought to determine the risk for specific complications with the duration of bacteremia. METHODS: We retrospectively reviewed all cases of SAB between 1 January 2017 and 31 December 2017 at a 500-bed academic hospital. Adult patients (≥18 years) with at least one blood culture positive for S. aureus were identified. Patients were excluded if withdrawal of care or death occurred within 48 hours of blood culture results or if the infection was associated with a ventricular assist device. Medical records were reviewed for the duration of bacteremia, complications, treatment decisions and clinical outcomes. This study was approved by the Institutional Review Board. RESULTS: One hundred forty-two discrete episodes of SAB were identified with a median age of 54 years (IQR 40–63). Most cases were community-acquired (83.8%) and 33.8% were MRSA. Active injection drug use was present in 22.5% (33.3% MRSA, 17% MSSA). The median duration of bacteremia was 2.6 days (IQR 1.8–4.6) and 3.9 days (IQR 2.2–7.5) for MSSA and MRSA, respectively. The median time to first source control procedure was twice as long with bacteremia over 5 days than with a shorter duration of bacteremia (2.6 vs. 1.3 days). Complication rates increased with bacteremia duration and bacteremia longer than 5 days was associated with significantly higher rates of endocarditis (46.2%, P < 0.001), epidural abscesses (35.9%, P = 0.001), intracranial infections (12.8%, P = 0.02), and presence of at least one endovascular nidus (76.9%, P < 0.001) compared with bacteremia less than 5 days (28.4%), but 30 day mortality rates were similar (7.7% and 9.8%, respectively). CONCLUSION: Complication rates increase significantly with SAB greater than 5 days duration. Early source control and investigation to identify metastatic and especially endovascular foci of infection are paramount in patients with prolonged bacteremia even if complications are not discovered on initial evaluation. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810339
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68103392019-10-28 209. What’s So Complicated About Complicated Staphylococcus aureus Bacteremia: Does Day 5 Matter? Hilsendager, Cami Strnad, Luke Open Forum Infect Dis Abstracts BACKGROUND: Prolonged Staphylococcus aureus bacteremia (SAB) poses challenges in clinical practice, particularly when a source is not readily identified. While SAB greater than 3 days has been identified as a risk factor for complications, little is known about risk for specific complications with each successive day of bacteremia. We sought to determine the risk for specific complications with the duration of bacteremia. METHODS: We retrospectively reviewed all cases of SAB between 1 January 2017 and 31 December 2017 at a 500-bed academic hospital. Adult patients (≥18 years) with at least one blood culture positive for S. aureus were identified. Patients were excluded if withdrawal of care or death occurred within 48 hours of blood culture results or if the infection was associated with a ventricular assist device. Medical records were reviewed for the duration of bacteremia, complications, treatment decisions and clinical outcomes. This study was approved by the Institutional Review Board. RESULTS: One hundred forty-two discrete episodes of SAB were identified with a median age of 54 years (IQR 40–63). Most cases were community-acquired (83.8%) and 33.8% were MRSA. Active injection drug use was present in 22.5% (33.3% MRSA, 17% MSSA). The median duration of bacteremia was 2.6 days (IQR 1.8–4.6) and 3.9 days (IQR 2.2–7.5) for MSSA and MRSA, respectively. The median time to first source control procedure was twice as long with bacteremia over 5 days than with a shorter duration of bacteremia (2.6 vs. 1.3 days). Complication rates increased with bacteremia duration and bacteremia longer than 5 days was associated with significantly higher rates of endocarditis (46.2%, P < 0.001), epidural abscesses (35.9%, P = 0.001), intracranial infections (12.8%, P = 0.02), and presence of at least one endovascular nidus (76.9%, P < 0.001) compared with bacteremia less than 5 days (28.4%), but 30 day mortality rates were similar (7.7% and 9.8%, respectively). CONCLUSION: Complication rates increase significantly with SAB greater than 5 days duration. Early source control and investigation to identify metastatic and especially endovascular foci of infection are paramount in patients with prolonged bacteremia even if complications are not discovered on initial evaluation. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810339/ http://dx.doi.org/10.1093/ofid/ofz360.284 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hilsendager, Cami
Strnad, Luke
209. What’s So Complicated About Complicated Staphylococcus aureus Bacteremia: Does Day 5 Matter?
title 209. What’s So Complicated About Complicated Staphylococcus aureus Bacteremia: Does Day 5 Matter?
title_full 209. What’s So Complicated About Complicated Staphylococcus aureus Bacteremia: Does Day 5 Matter?
title_fullStr 209. What’s So Complicated About Complicated Staphylococcus aureus Bacteremia: Does Day 5 Matter?
title_full_unstemmed 209. What’s So Complicated About Complicated Staphylococcus aureus Bacteremia: Does Day 5 Matter?
title_short 209. What’s So Complicated About Complicated Staphylococcus aureus Bacteremia: Does Day 5 Matter?
title_sort 209. what’s so complicated about complicated staphylococcus aureus bacteremia: does day 5 matter?
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810339/
http://dx.doi.org/10.1093/ofid/ofz360.284
work_keys_str_mv AT hilsendagercami 209whatssocomplicatedaboutcomplicatedstaphylococcusaureusbacteremiadoesday5matter
AT strnadluke 209whatssocomplicatedaboutcomplicatedstaphylococcusaureusbacteremiadoesday5matter